Your session is about to expire
← Back to Search
Teprotumumab for Graves' Ophthalmopathy
Study Summary
This trial involves testing a new treatment for proptosis in a blinded study where some participants will receive the treatment and others will receive a placebo. Participants who do not respond to the initial treatment may have
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 83 Patients • NCT03298867Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this study include individuals who are older than 60 years of age?
"Recruitment for this research is targeting individuals aged above 18 and below 80 years."
Are new participants still eligible to enroll in this ongoing clinical trial?
"Indeed, as per clinicaltrials.gov, this trial is presently in the recruitment phase. The initial posting date was February 21st, 2024 and the latest update occurred on March 22nd, 2024. A total of 80 participants are sought from a single designated site."
How large is the patient population participating in this medical study?
"Indeed, the details on clinicaltrials.gov signify that this trial is presently seeking volunteers. This particular research initiative was initially made available on February 21st, 2024, and had its most recent revision on March 22nd, 2024. The investigation aims to enroll a total of 80 participants from just one location."
Has Teprotumumab been officially sanctioned by the FDA for utilization?
"Our experts at Power rate the safety of Teprotumumab as 3 on a scale of 1 to 3 due to being in Phase III, indicating existing efficacy data and repeated safety assessments."
Share this study with friends
Copy Link
Messenger